CanBas Co

CanBas Co Net Margin

The Net Profit Margin of CanBas Co (4575.T) as of Oct 19, 2026 is -1,599.78 %. In the previous year, Net Profit Margin was -487.43 % — a change of 228.20% (lower).

Net Margin

-1,599.78 %

YoY

228.20%

Last updated:

Net Profit Margin of CanBas Co is 2022 -1,599.78 % . Net Profit Margin of CanBas Co was 2021 -487.43 % . It decreases by 228.20% lower compared to the previous year.

For CanBas Co, the net margin of -1,599.8% is down versus -483.7% a few years ago.

The CanBas Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2015
-437.95 JPY
Jan 1, 2016
-394.32 JPY
Jan 1, 2017
-381.88 JPY
Jan 1, 2018
-483.72 JPY
Jan 1, 2019
-394.81 JPY
Jan 1, 2020
-520.72 JPY
Jan 1, 2021
-487.43 JPY
Jan 1, 2022
-1,599.78 JPY
The CanBas Co Net Margin history
YEARNet MarginYoY
-1,599.78 %+228.20%
-487.43 %-6.39%
-520.72 %+31.89%
-394.81 %-18.38%
-483.72 %+26.67%
-381.88 %-3.15%
-394.32 %-9.96%
-437.95 %-121,803.59%
0.36 %-126.14%
-1.38 %+86.84%
-0.74 %-90.18%
-7.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co Ltd is a biotechnology company based in Numazu-shi, Japan, operating within the healthcare sector. The company has a small team of 12 employees and went public on September 17, 2009, with its ticker listed as 4575.T and ISIN JP3244570002. Its primary focus is on anticancer drug discovery research, which includes developing drug discovery concepts, selecting candidate compounds through method-based approaches, conducting simple animal studies, and analyzing basic data on anticancer drug candidates entering development. Additionally, CanBas engages in early clinical development activities, such as preclinical studies required before submitting applications for clinical trials and conducting the initial phases of clinical trials. The company maintains a website at https://www.canbas.co.jp/ for further information. CanBas operates as a private entity with a minimal workforce, emphasizing research and development in the early stages of anticancer drug development. It does not provide details on specific products, acquisitions, or financial figures beyond its IPO date and employee count. The company's headquarters are located in Numazu-shi, Shizuoka Prefecture, Japan, and it is listed on the Tokyo Stock Exchange. Its operations are centered around foundational research in oncology, aiming to contribute to the discovery and development of new anticancer treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Net Profit Margin of CanBas Co is -1,599.78 % in 2022.

Net Profit Margin of CanBas Co changed from -487.43 % to -1,599.78 %, representing a 228.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin CanBas Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's CanBas Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — CanBas Co

All Key Metrics — CanBas Co